Related Experiment Video
Updated: May 3, 2026
15:43
Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
Published on: March 17, 2014
23.0K
[Why use long-term macrolide therapy in pediatric pulmonology?]
H Corvol1, J Taytard1, G Thouvenin1
1Service de pneumologie pédiatrique, hôpital Trousseau, AP-HP, centre de ressources et de compétences pour la mucoviscidose, centre de référence des maladies respiratoires rares, université Pierre-et-Marie-Curie-Paris 6, unité Inserm U938, 26, avenue du Dr-Netter, 75012 Paris, France.
Summary
Long-term macrolide antibiotics show benefits in chronic pediatric respiratory diseases like cystic fibrosis and asthma. This review explores their impact on various lung conditions, including diffuse parenchymal lung diseases.
Area of Science:
- Pharmacology
- Immunology
- Pulmonology
Context:
- Macrolides are antibiotics with known antimicrobial, anti-inflammatory, and immunomodulatory properties.
- Long-term macrolide use is established for diffuse panbronchiolitis, improving lung disease and survival.
- Chronic respiratory diseases present significant challenges in pediatric populations.
Purpose:
- To review clinical trial data on long-term macrolide use in pediatric chronic respiratory diseases.
- To evaluate macrolide efficacy in cystic fibrosis, non-cystic fibrosis bronchiectasis, and asthma.
- To explore potential macrolide applications in diffuse parenchymal lung diseases.
Summary:
- This review synthesizes evidence from trials investigating long-term macrolide therapy in pediatric cystic fibrosis, non-cystic fibrosis bronchiectasis, and asthma.
- Findings highlight macrolides' positive impact on disease management and outcomes in these conditions.
- The review also examines emerging data on macrolides for diffuse parenchymal lung diseases.
Impact:
- Provides a comprehensive overview of macrolides' role in managing chronic pediatric lung diseases.
- Offers insights into potential new therapeutic strategies for diffuse parenchymal lung diseases.
- Supports evidence-based clinical decision-making for long-term antibiotic use in respiratory medicine.
Related Concept Videos
01:28Pulmonary Tuberculosis V
1.0K
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
1.0K
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
408
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
408
01:26COPD: Management Using Bronchodilators and Corticosteroids
1.2K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.2K
01:17Drugs Used in Lower Respiratory Disorders: Overview
1.6K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.6K
01:19Antiasthma Drugs: Leukotriene Modifiers
2.2K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.2K
01:14Atypical Pneumonia
84
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
84